NRBdMF: A recommendation algorithm for predicting drug effects considering directionality

• URL: http://arxiv.org/abs/2208.04312v1
• Date: Fri, 5 Aug 2022 04:58:14 GMT
• Title: NRBdMF: A recommendation algorithm for predicting drug effects considering directionality
• Authors: Iori Azuma, Tadahaya Mizuno, Hiroyuki Kusuhara
• Abstract summary: We propose using neighborhood regularized bidirectional matrix factorization (NRBdMF) to predict drug effects by incorporating bidirectionality. This first attempt to consider the bidirectional nature of drug effects using NRBdMF showed that it reduced false positives and produced a highly interpretable output.
• Score: 0.0
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Predicting the novel effects of drugs based on information about approved drugs can be regarded as a recommendation system. Matrix factorization is one of the most used recommendation systems and various algorithms have been devised for it. A literature survey and summary of existing algorithms for predicting drug effects demonstrated that most such methods, including neighborhood regularized logistic matrix factorization, which was the best performer in benchmark tests, used a binary matrix that considers only the presence or absence of interactions. However, drug effects are known to have two opposite aspects, such as side effects and therapeutic effects. In the present study, we proposed using neighborhood regularized bidirectional matrix factorization (NRBdMF) to predict drug effects by incorporating bidirectionality, which is a characteristic property of drug effects. We used this proposed method for predicting side effects using a matrix that considered the bidirectionality of drug effects, in which known side effects were assigned a positive label (plus 1) and known treatment effects were assigned a negative (minus 1) label. The NRBdMF model, which utilizes drug bidirectional information, achieved enrichment of side effects at the top and indications at the bottom of the prediction list. This first attempt to consider the bidirectional nature of drug effects using NRBdMF showed that it reduced false positives and produced a highly interpretable output.

Related papers

• DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization [53.27954325490941]
  Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
  arXiv  Detail & Related papers  (2025-02-11T04:00:21Z)
• Causal machine learning for predicting treatment outcomes [75.13093479526151]
  Causal machine learning (ML) offers flexible, data-driven methods for predicting treatment outcomes. Key benefit of causal ML is that it allows for estimating individualized treatment effects.
  arXiv  Detail & Related papers  (2024-10-11T12:39:08Z)
• ADRNet: A Generalized Collaborative Filtering Framework Combining Clinical and Non-Clinical Data for Adverse Drug Reaction Prediction [49.56476929112382]
  Adverse drug reaction (ADR) prediction plays a crucial role in both health care and drug discovery. We propose ADRNet, a generalized collaborative filtering framework combining clinical and non-clinical data for drug-ADR prediction.
  arXiv  Detail & Related papers  (2023-08-03T11:28:12Z)
• Benchmarking Bayesian Causal Discovery Methods for Downstream Treatment Effect Estimation [137.3520153445413]
  A notable gap exists in the evaluation of causal discovery methods, where insufficient emphasis is placed on downstream inference. We evaluate seven established baseline causal discovery methods including a newly proposed method based on GFlowNets. The results of our study demonstrate that some of the algorithms studied are able to effectively capture a wide range of useful and diverse ATE modes.
  arXiv  Detail & Related papers  (2023-07-11T02:58:10Z)
• An Efficient Doubly-Robust Test for the Kernel Treatment Effect [31.522078399310466]
  We propose a new kernel-based test for distributional effects of the treatment. It is to the best of our knowledge, the first kernel-based, doubly-robust test with provably valid type-I error.
  arXiv  Detail & Related papers  (2023-04-26T01:56:34Z)
• On the Challenges of using Reinforcement Learning in Precision Drug Dosing: Delay and Prolongedness of Action Effects [42.84123628139412]
  Two major challenges of using RL for drug dosing are delayed and prolonged effects of administering medications. We propose a simple and effective approach to converting drug dosing PAE-POMDPs into MDPs. We validate the proposed approach on a toy task, and a challenging glucose control task, for which we devise a clinically-inspired reward function.
  arXiv  Detail & Related papers  (2023-01-02T03:16:59Z)
• NESTER: An Adaptive Neurosymbolic Method for Causal Effect Estimation [37.361149306896024]
  Causal effect estimation from observational data is a central problem in causal inference. We propose an adaptive method called Neurosymbolic Causal Effect Estimator (NESTER) Our comprehensive empirical results show that NESTER performs better than state-of-the-art methods on benchmark datasets.
  arXiv  Detail & Related papers  (2022-11-08T16:48:46Z)
• Graph Regularized Probabilistic Matrix Factorization for Drug-Drug Interactions Prediction [18.659559002642784]
  Co-administration of two or more drugs simultaneously can result in adverse drug reactions. Identifying drug-drug interactions (DDIs) is necessary, especially for drug development and for repurposing old drugs. This paper presents a novel Graph Regularized Proabilistic Matrix Factorization (MF) method, which incorporates expert knowledge through a novel graph-based regularization strategy.
  arXiv  Detail & Related papers  (2022-10-19T12:33:06Z)
• Reenvisioning Collaborative Filtering vs Matrix Factorization [65.74881520196762]
  Collaborative filtering models based on matrix factorization and learned similarities using Artificial Neural Networks (ANNs) have gained significant attention in recent years. Announcement of ANNs within the recommendation ecosystem has been recently questioned, raising several comparisons in terms of efficiency and effectiveness. We show the potential these techniques may have on beyond-accuracy evaluation while analyzing effect on complementary evaluation dimensions.
  arXiv  Detail & Related papers  (2021-07-28T16:29:38Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases [60.07352590494571]
  The aim of this study was to extend this approach to the observational setting using a standardized scalable framework. We demonstrate our framework by evaluating the effect of angiotensin-converting enzyme (ACE) inhibitors versus beta blockers on three efficacy and six safety outcomes.
  arXiv  Detail & Related papers  (2020-10-13T14:48:31Z)
• A Node Embedding Framework for Integration of Similarity-based Drug Combination Prediction [7.4517333921953215]
  We propose a Network Embedding framework in Multiplex Networks (NEMN) to predict synthetic drug combinations. Based on a multiplex drug similarity network, we offered alternative methods to integrate useful information from different aspects. For Drug combination prediction, we found seven novel drug combinations which have been validated by external sources.
  arXiv  Detail & Related papers  (2020-02-25T02:24:47Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.